Inverness Medical Innovations invests $92.5 million in Abbott rapid diagnostic lines
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations has acquired a package of rapid diagnostic product lines from Abbott Laboratories for $92.5m in cash and stock. The products, 90% of which test for pregnancy and streptococcal infection, are currently worth around $50m in annual revenues to IMI, CEO Ron Zwanziger said.